Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 478-487

  Robinson, David ^a   Garmo, Hans ^a   Lindahl, Bertil ^a   Van Hemelrijck, Mieke ^a   Adolfsson, Jan ^a   Bratt, Ola ^a   Holmberg, Lars ^a   Stattin, Pär ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

drug therapy; myocardial ischemia; prostatic neoplasms; stroke

Indexed keywords

GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER REGISTRY; CONTROLLED STUDY; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK ASSESSMENT; STROKE; SWEDEN;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; MYOCARDIAL ISCHEMIA; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; STROKE; SWEDEN;

EID: 83655167401     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26022     Document Type: Article

References (25)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
2. Nair B, Wilt T, MacDonald R, Rutks I,. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002: 1; CD003506.
3. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR,. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 1708-14.
4. Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K,. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009; 56: 609-16.
5. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23.
6. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J,. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950-8.
7. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW,. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5.
8. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR,. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-24.
9. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS,. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-500.
10. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF,. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8.
11. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
12. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56.
13. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J,. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010; 28: 3448-56.
14. Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Stattin P, Tornblom M, Johansson JE,. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 117-23.
15. Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P,. PCBaSe Sweden: A register-based resource for prostate cancer research. Scand J Urol Nephrol 2009; 43: 342-9.
16. Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J,. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008; 180: 2423-9; discussion 9-30.
17. Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelson A, Bratt O, Damber JE, Hellstrom K, Hellstrom M, Holmberg E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456-77.
18. UICC (Union internationale Contre le Cancer). TNM classification of malignant tumours, 6th edn. Geneva (Switzerland): International Union Against Cancer, 2002.
19. Central Bureau for Statistics. Statistics Sweden. Stockholm, Sweden. Available at:. Accessed on 17 November 2010.
20. The national board of health and welfare. Causes of death 1996-2005. Available at:, 2007. Accessed on 17 November 2010.
21. Hammar N, Alfredsson L, Rosen M, Spetz CL, Kahan T, Ysberg AS,. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol 2001; 30 (Suppl 1): S30-S4.
22. Ingelsson E, Arnlov J, Sundstrom J, Lind L,. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005; 7: 787-91.
23. Lindblad U, Rastam L, Ranstam J, Peterson M,. Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project. Scand J Soc Med 1993; 21: 3-9.
24. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Prostate Cancer. Version 1. 2010. Available at:. Accessed on 17 November 2010.
25. Hallas J, Gaist D, Bjerrum L,. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997; 8: 666-70.